Conversation with The Cancer LetterRegulatory News FDA says it had no input as companies developed checkpoint inhibitors in China February 04, 2022Vol.48 No.05By Paul Goldberg
Regulatory News FDA cancels second ODAC in a row as two accelerated approval drugs are yanked by sponsors (and one still dangles) December 03, 2021Vol.47 No.44By Alice Tracey
